Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics.
about
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusDalbavancin: a novel antimicrobialSynthesis and Characterization of the Arylomycin Lipoglycopeptide Antibiotics and the Crystallographic Analysis of Their Complex with Signal PeptidaseStructure of the complex between teicoplanin and a bacterial cell-wall peptide: use of a carrier-protein approachA Carrier Protein Strategy Yields the Structure of DalbavancinNewer antibacterial drugs for a new century.Solid- and solution-phase synthesis of vancomycin and vancomycin analogues with activity against vancomycin-resistant bacteria.Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: target-accelerated combinatorial synthesis.Living with an imperfect cell wall: compensation of femAB inactivation in Staphylococcus aureus.Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.Induction kinetics of the Staphylococcus aureus cell wall stress stimulon in response to different cell wall active antibioticsVancomycin analogs: Seeking improved binding of d-Ala-d-Ala and d-Ala-d-Lac peptides by side-chain and backbone modifications.glmM operon and methicillin-resistant glmM suppressor mutants in Staphylococcus aureus.Teicoplanin stress-selected mutations increasing sigma(B) activity in Staphylococcus aureus.A novel membrane protein, VanJ, conferring resistance to teicoplanin.Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.Molecular interactions of glycopeptide antibiotics investigated by affinity capillary electrophoresis and bioaffinity electrospray ionization-mass spectrometry.Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate.Mechanism of action of oritavancin and related glycopeptide antibiotics.Novel antibacterial agents for the treatment of serious Gram-positive infections.Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococciInitial efforts toward the optimization of arylomycins for antibiotic activity.Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics.The effect of environment on the recognition and binding of vancomycin to native and resistant forms of lipid II.Clostridium difficile drug pipeline: challenges in discovery and development of new agentsTargeted delivery of vancomycin to Staphylococcus epidermidis biofilms using a fibrinogen-derived peptide.In vitro activity of alpha-mangostin in killing and eradicating Staphylococcus epidermidis RP62A biofilms.Dalbavancin: a new option for the treatment of gram-positive infections.Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureusTelavancin: a novel lipoglycopeptide for serious gram-positive infections.Review of dalbavancin, a novel semisynthetic lipoglycopeptide.Hydrophobic side-chain length determines activity and conformational heterogeneity of a vancomycin derivative bound to the cell wall of Staphylococcus aureus.Locations of the hydrophobic side chains of lipoglycopeptides bound to the peptidoglycan of Staphylococcus aureusA review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).Vancomycin resistance: are there better glycopeptides coming?Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureusVancomycin and oritavancin have different modes of action in Enterococcus faeciumVancomycin derivative with damaged D-Ala-D-Ala binding cleft binds to cross-linked peptidoglycan in the cell wall of Staphylococcus aureus.Biosynthesis, biotechnological production, and application of teicoplanin: current state and perspectives.Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.
P2860
Q24556635-49105722-4528-455B-A9C8-EE368FC5EB03Q24674841-C347AAAF-4AE2-41D2-A69A-0B02D07964E2Q27675041-BF1B6151-B274-4A70-B041-8E9AB7F16D11Q27676948-4C2E61EA-F8D1-4C58-8D5A-6035239E713CQ27677393-DCA7A682-1CDA-4A6E-8775-D0D337CAE879Q30433333-B1756977-C668-414B-A55C-376180E9CE58Q30725913-1C271F36-35C4-40CC-A9A6-30329F7DCF1EQ30725927-0CB8E97A-8C3C-44DE-8DC6-F7B25BFC466DQ33296902-4FFDAF5A-0FFD-406F-9490-41571E23C848Q33698979-456DC479-25C1-4799-A42B-2765C96E56D5Q33798586-4F369534-27D3-4190-8E3A-4618BC7DA34CQ33944429-41734D72-1656-4547-83BB-F345B0FAFEE6Q33975995-02A488D6-4B11-4E90-85F4-CE494B51A12EQ33982248-AB46F70E-3238-46A3-B48B-DD89AC4C6849Q34122537-26767CB7-7443-4482-9437-E5A4607DA13BQ34448260-26EAB013-9C2B-4E53-8E06-90E11DC16DC4Q34580560-6C3FD0D0-7D38-440B-8D80-8FC3C5EF8FC6Q35021822-EA640F20-5943-4EFC-BF66-869CD3954CAAQ35066202-F40E86CC-D99A-4BAF-979A-026994CE6073Q35073345-BE71A739-BCA5-4400-B9EE-3F7B628E5037Q35127151-A8028CFC-3A0C-40FC-86D6-2898A22853B3Q35149887-5033626C-DC04-45AE-82C4-B361071A2DB5Q35610665-34D2B3C3-3D2B-45DB-9EE6-A98B519F7262Q35815846-B9AC9747-9455-458D-A135-42E01F8D4641Q35846436-26A9E8AE-36D6-4D71-B31C-5016AA5AC2A4Q36289983-D7148CC0-0F47-4EEB-B3F2-450D5074F364Q36323203-BA118E81-F028-4A1F-BAFD-4E6601C32D84Q36409507-C7500CDB-D41D-456A-ACC9-89F0355EB769Q36512904-F34095CC-6582-4F09-9938-202C914AFFB0Q36736356-DF287C69-CE71-4358-A6DC-1A3DF7A5B27DQ36802632-7CB99864-4097-4340-B9C8-72AF71F13ED9Q37130388-EAC4358C-3817-43B6-B42D-88B4A23419CEQ37185364-F9D3E79D-70FB-4692-A2A4-A074C30202B3Q37252733-5F8E7370-B4C0-4F2B-8FED-990B5CC931D7Q37340562-9AC1D1AB-37E8-445E-91D3-07497FF3093CQ37355272-6FB8B969-8117-491E-8CEB-3FA1031B0E64Q37356329-8ADAF646-F4F9-45A8-94A6-A84A79CDAEE8Q37423397-7CD1B14D-91CA-421C-86D8-8AFE5DCC213FQ37554018-37FCE831-EB95-4B0E-81DB-52ABFEBF2B8CQ38233471-7567A041-81E2-4A02-83C1-B62B5F15BCE9
P2860
Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Dimerization and membrane anch ...... vancomycin group antibiotics.
@en
Dimerization and membrane anch ...... vancomycin group antibiotics.
@nl
type
label
Dimerization and membrane anch ...... vancomycin group antibiotics.
@en
Dimerization and membrane anch ...... vancomycin group antibiotics.
@nl
prefLabel
Dimerization and membrane anch ...... vancomycin group antibiotics.
@en
Dimerization and membrane anch ...... vancomycin group antibiotics.
@nl
P2093
P2860
P356
P1476
Dimerization and membrane anch ...... vancomycin group antibiotics.
@en
P2093
Beauregard DA
Knowles DJ
Williams DH
P2860
P304
P356
10.1128/AAC.39.3.781
P407
P577
1995-03-01T00:00:00Z